Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 4691  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (147 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   Abstract
   Introduction
   Materials and Me...
   Results
   Discussion
   Acknowledgement
   References
   Article Tables

 Article Access Statistics
    Viewed5323    
    Printed148    
    Emailed3    
    PDF Downloaded232    
    Comments [Add]    
    Cited by others 6    

Recommend this journal

 


 
ORIGINAL ARTICLE
Year : 2006  |  Volume : 54  |  Issue : 2  |  Page : 182-185

Investigation on mtDNA deletions and twinkle gene mutation (G1423C) in Iranian patients with chronic progressive external opthalmoplagia


1 Department of Medical Genetics, National Institute for Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran
2 Farabi Eye's Hospital, Tehran, Iran

Correspondence Address:
Massoud Houshmand
Department of Medical Genetics, National Institute for Genetic Engineering and Biotechnology (NIGEB), 17th Km Tehran-Karaj highway, Pajoohesh Blvd, P.O.Box 14155-6343, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 16804265

Rights and PermissionsRights and Permissions

  Abstract 

Background: Chronic progressive external ophthalmoplagia (CPEO) is a phenotypic mitochondrial disorder that affects external ocular and skeletal muscles and is associated with a single or multiple mitochondrial DNA (mtDNA) deletions and also nuclear gene mutations. There are also some reports about the relationship between CPEO and the nuclear Twinkle gene which encodes a kind of mitochondrial protein called Twinkle. Aims: To study the mtDNA deletions and Twinkle gene G1423C point mutation in Iranian patients with CPEO. Materials and Methods: We collected 23 muscle samples from patients with CPEO, 9 women (mean age 34.3 years) and 14 men (36.7 years). Multiplex polymerase chain reaction (PCR) method was used to find the presence of single or multiple deletions in mtDNA. Single stranded conformational polymorphism (SSCP) and restriction fragment length polymorphism (PCR-RFLP) methods were carried out to investigate point mutation (G1423C) in the Twinkle gene in all DNA samples. Results: Different sizes of mtDNA deletions were detected in 16 patients (69.6%). Each of the 5.5, 7, 7.5 and 9 kb deletions existed only in 1 patient. Common deletion (4977bp) and 8 kb deletion were detected in 5 and 3 patients respectively. Multiple deletions were also present in 4 patients. Out of 23 patients included in our study, two cases (8.7%) had Twinkle gene mutation (G1423C) and 5 patients (21.7%) did not show any deletions in mtDNA or the Twinkle gene mutation. Conclusion: Our study provides evidence that the investigation of mtDNA and Twinkle gene mutations in CPEO may help with early diagnosis and prevention of the disease. Patients who did not show deletions in the mtDNA or G1423C mutation in the Twinkle gene may have other mtDNA, Twinkle or nuclear gene mutations.


Keywords: CPEO, Mitochondria, mtDNA deletion, Twinkle gene.


How to cite this article:
Houshmand M, Panahi MS, Hosseini B N, Dorraj G H, Tabassi A R. Investigation on mtDNA deletions and twinkle gene mutation (G1423C) in Iranian patients with chronic progressive external opthalmoplagia. Neurol India 2006;54:182-5

How to cite this URL:
Houshmand M, Panahi MS, Hosseini B N, Dorraj G H, Tabassi A R. Investigation on mtDNA deletions and twinkle gene mutation (G1423C) in Iranian patients with chronic progressive external opthalmoplagia. Neurol India [serial online] 2006 [cited 2020 Apr 2];54:182-5. Available from: http://www.neurologyindia.com/text.asp?2006/54/2/182/25972



  Introduction Top


Chronic progressive external ophthalmoplagia (CPEO) is a disorder characterized by the slow progressive weakness of the extra ocular muscles. Patients usually experience bilateral, symmetrical and progressive ptosis, followed by ophthalmoparesis. Ciliary body and iris muscles are not involved in these patients.[1] Deletions of mitochondrial DNA (mtDNA), a few bases to 10 kb in size, were detected in more than 70% of patients with CPEO.[2] mtDNA is a small 16569bp molecule of double stranded DNA and encodes 13 protein subunits of multimeric oxidative phosphorylation, 2 ribosomal RNAs (rRNA) and all the translated RNAs (tRNA) required for the translation of its messenger RNA (mRNA).[3],[4] Sporadic germline and maternally inherited mutations of mtDNA, including single deletions/duplications and point mutations, are a frequent cause of human disease.[3],[4],[5] Deletions of various lengths of mtDNA result in defective mitochondrial function, particularly in highly oxidative tissues (e.g., muscle, brain and heart). Extra ocular muscles are affected preferentially because their fraction of mitochondrial volume is several times greater than that of other skeletal muscles.[6],[7],[8],[9],[10] The nuclear background of the autosomal dominant or recessive progressive external ophthalmoplegia (ad/arPEO) with multiple mtDNA deletions has been already established.[11],[12],[13]

To date, mutations in three nuclear genes have been linked to this disorder. These include the muscle-brain and heart-specific isoform of the adenine nucleotide translocator 1 (ANT1) genes,[14] C10 or f2 encoding a putative mitochondrial helicase (Twinkle)[15] and the sole mtDNA polymerase (pol g) gene (POLG).[16] The heterozygous, missense GC transversion at bp 1423 in the C10 or f2 gene, results in an amino acid change of Ala-475 to Pro (A475P) has already been reported in a large Pakistani family.[15]

We studied 23 clinically diagnosed Iranian patients with CPEO to identify mtDNA deletions and Twinkle gene mutation (G1423C).


  Materials and Methods Top


Consecutive patients with CPEO referred for evaluation to Medical Genetics Department of the National Institute for Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran over a period of 17 months (from June 2002 to December 2004) were the subjects of the study. The study protocol has the approval of the Institute Ethics Committee. Written informed consent was obtained from all the patients for the use of muscle biopsy for the study.

Muscle biopsies of 23 patients with CPEO were analyzed; 9 women, (mean age 34.3, range 30-40 yrs) and 14 men (mean age 36.7, range 32-43 yrs). Patients with CPEO with no family history of the disease and aged 18 years or above were included in the study. Patients were fully worked-up to exclude other causes of external ophthamoplegia.

DNA Extraction Kit (Diatom, GenFanavaran, Tehran, Iran) was used to extract DNA from the skeletal muscle biopsy material. Primers used are given in [Table - 1]. Using primers ONP 86F, ONP 89R, ONP 10R, ONP 74R, ONP 25F and ONP 99R investigated the deletion-prone regions between 5461bp of the light strand and 15000bp of the heavy strand. Amplification of mtDNA was only possible if a part of the DNA between respective primers was deleted. Primers ONP 86F and ONP89R were used to amplify a normal internal mtDNA fragment in a region, which is seldom afflicted by deletions and served as a control for PCR analysis. Polymerase chain reaction (PCR) studies were performed in a total volume of 25 l including 100 ng of total DNA, 0.2 mM of each dNTPs, 2 pmol of each primer, 5 mM KCL, 200 mM TRIS-HCL (PH=8.4), 1.5 mM mgcl 2 and 1.5 unit of Taq polymerase. (Roche, Inc) PCR reaction were carried out in a MWG Thermocycler (Germany) using the following program: 94C for 5 min as initial denaturation and then amplification was accomplished in 36 cycles at following temperature: denaturing at 94 C for 1 min, annealing at 57C for 50 sec and 1 min at 72 C for elongation, followed by a final extension at 72 C for 10 min. PCR products were electrophoresed on 3% agarose gel and stained with ethidium bromide. In some patients, deletion break points were confirmed by sequencing of DNA fragments amplified by the PCR reactions, using the ABI 3100 and 3700 capillary sequencer. In order to investigate point mutation (G1423C) in the Twinkle gene, the method of single stranded conformational polymorphism (SSCP) was applied to all DNA samples. Then restriction fragment length polymorphism (PCR-RFLP) technique was applied to samples positive for single stranded conformational polymorphism (SSCP). All DNA samples were amplified by the PCR method. PCR was carried out with primers Tw-ex2-If (5'- ctc ctc acc cag gtg gtc tgt tc-3') and Tw-ex2- IR (5'- ccc tgc cct ctc att ctt tg-3'). PCR program used was: 94c for 5 min (initial denaturation), 94c for 30'', 57c for 45'', 72c for 1 min (36 cycles) and 72C for 10 min (final extension). SSCP was applied to the 413 bp amplified fragments following denaturation and separation on 8% poly acrylamide gels. Positive samples were further evaluated for the presence of the Twinkle gene (G1423C) mutation by using the HaeII restriction enzyme in the RFLP procedure. Samples positive for the G1423C mutation were further confirmed by sequencing with the Tw-ex2-If primer.


  Results Top


Of the 23 patients with CPEO studied, 16 (69.6%) patients showed single deletion in the mtDNA, 2 (8.7%) patients showed G1423C mutation in the Twinkle gene without deletion in the mtDNA and the remaining 5 (21.7%) did not show any deletions in the mtDNA or mutation in the Twinkle gene. Five patients had common deletion (4977bp). While each of the 5.5, 7, 7.5 and 9 kb deletions was exclusively present only in a single patient, 8 kb deletion existed in 3 patients. Multiple deletions were found in 4 patients. [Table 2] In the SCCP and sequencing experiments, two patients showed different bands in comparison with the normal control. The G1423C mutation was detected in 2 women. Patients with the G1423C mutation showed the following fragments: 177bp, 201bp, 35bp, 378bp, whereas healthy individuals showed fragments 35bp, 378bp. The average age of onset in patients with the A475P mutation was 19 and 23 years. Two patients with A475P mutation in addition to CPEO had other clinical features such as proximal muscle weakness, ataxia, neuropathy, depression or avoidant personality traits, pes cavus and tremors.


  Discussion Top


The major aim of this study was to evaluate the prevalence of mtDNA deletions and Twinkle gene mutations (A475P) in Iranian patients with CPEO. It has been shown that POLG mutations cause arPEO and this gene has a crucial role in the mtDNA replication machinery.[17] Single mtDNA deletions may occur in sporadic cases, but multiple deletions of mtDNA also occur in autosomal dominant disorders.

AdPEO was first diagnosed in several families. Generalized weakness of the skeletal muscles and sudden unexpected death are common clinical features of AdPEO.[18],[19],[20],[21],[22] In a study of two families of adPEO, Kiechl et al[23] demonstrated a novel pathogenic mutation in Twinkle (F485L). Deschauer et al[24] described a family with adPEO caused by a novel heterozygous A to C transversion at nucleotide 956 of the Twinkle gene. Mutations of ANT1, Twinkle and POLG1 in sporadic PEO have already been verified.[25] To the best of our knowledge, this is the first study describing A475P mutation in Iranian patients. In our study 69.6% of patients showed single mtDNA deletions, 8.7% showed G1423C mutations in their Twinkle genes without mtDNA multiple deletions and the remaining 5 patients (21.7%) did not show any Twinkle gene mutations or deletions in the mtDNA. Arenas et al[26] analyzed Twinkle gene mutations in 11 Australian families with adPEO and investigated whether there were any distinct molecular and clinical features associated with this mutations. They found that multiple deletions in the mtDNA were not always prominent and there were significant variations in the clinical presentation within and between families with mutations in the Twinkle gene. We propose that patients with G1423C mutation in the Twinkle gene are heterozygotes with dominant phenotypes. They have a negative family history of adPEO, so it is possible that G1423C mutation has occurred sporadically as a germline mutation in the Twinkle gene. Further studies are required to reveal this in their siblings. Guilegy et al[27] had described this novel phenotype for twinkle gene mutations and multiple mtDNA deletion syndromes in a patient with no documented family history of PEO. These observations suggests either a sporadic or an autosomal-recessive syndrome.[27] In our series two patients with Twinkle mutations had proximal muscle weakness, ataxia, neuropathy, depression or avoidant personality traits, pes cavus and tremors in addition to progressive external ophthalmoplegia. With the aid of multiplex PCR and primers, we were only able to test for large-scale deletions. Since our major aim was to evaluate patients with respect to large deletions (5 kb or more), small deletions might have been missed using our methods. (MITOMAP database)

The present study has some limitations. Because of the smaller number of patients, the exact significance of mutation in the Twinkle gene could not be established. Moreover, a larger number of patients need to be screened to find out the frequency of A475P mutation in the Iranian patients with CPEO. Regarding patients who did not show deletion in the mtDNA or G1423C mutation in the nuclear DNA, other mtDNA or nuclear gene mutations such as duplication of amino acids 352-364 of the Twinkle gene, the gene encoding PolG (15q22) and the 4q linked adPEO gene identified as ANT1 might have existed. We suggest follow-up studies on these patients. Investigation of mtDNA and Twinkle gene mutations in CPEO can help patients with early diagnosis and prevention. Screening of Twinkle gene mutations should be performed in all patients with PEO.


  Acknowledgement Top


This project supported by National Institute for Genetic Engineering and Biotechnology, Tehran Iran (Project No 183) and Farabi eye's Hospital, Tehran, Iran.

 
  References Top

1.Shimko, Jacqueline W. Chronic Progressive External Ophthalmoplegia. Am Orthopic J 2005;55:13-8.  Back to cited text no. 1    
2.Goto Y, Koga Y, Horai S, Nonaka I. Chronic progressive external ophthalmoplegia: a correlative study of mitochondrial DNA deletion and their phenotypic expression in muscle biopsies. J Neurol Sci 1990;100:63-9.  Back to cited text no. 2    
3.Satoh M, Kuroiwa T. Organization of multiple nucleoids and DNA molecules in mitochondria of a human cell. Exp Cell Res 1991;196:137-40.  Back to cited text no. 3    
4.Garrido N, Griparic L, Jokitalo E, Wartiovaara J, van der Bliek AM, Spelbrink JN. Composition and dynamics of human mitochondrial nucleoids. Mol Biol Cell 2003;14:1583-96.  Back to cited text no. 4    
5.Grossman LI, Shoubridge EA. Mitochondrial genetics and human disease. Bioessays 1996;18:983-91.  Back to cited text no. 5    
6.Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, et al . The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nature Genet 2001;29:337-41.   Back to cited text no. 6    
7.Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nature Genet 2001;29:342-4.   Back to cited text no. 7    
8.Van Goethem G, Martin JJ, Van Broeckhoven C. Progressive external ophthalmoplegia and multiple mitochondrial DNA deletions. Acta Neurol Belg 2002;102:39-42.  Back to cited text no. 8    
9.Ogasahara S, Nishikava Y, Yorifuji S, Soga F, Nagamura Y, Takahashi M, et al . Treatment of Kearns -Sayer syndrome with coenzyme Q10. Neurology 1986;36:45-53.  Back to cited text no. 9    
10.Chaturvedi S, Bala K, Thakur R, Suri V. Mitochondrial encephalomyopathies: advances in understanding. Med Sci Monit 2005;11:238-46.  Back to cited text no. 10    
11.Zeviani M, Servidei S, Gellera C, Bertini E, DiMauro S, DiDonato S. An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature 1989;339:309-11.  Back to cited text no. 11    
12.Zeviani M, Bresolin N, Gellera C, Bordoni A, Pannacci M, Amati P, et al . Nucleus-driven multiple large-scale deletions of the human mitochondrial genome: a new autosomal dominant disease. Am J Hum Genet 1990;47:904-14.  Back to cited text no. 12    
13.Hirano M, DiMauro S. ANT1, Twinkle, POLG and TP: new genes open our eyes to ophthalmoplegia. Neurology 2001;57:2163-5.  Back to cited text no. 13    
14.Kaukonen J, Juselius JK, Tiranti V, Kyttala A, Zeviani M, Comi GP, et al . Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 2000;289:782-5.  Back to cited text no. 14    
15.Spelbrink JN, Li FY, Tiranti V, Nikalia K, Yuan QP, Tariq M, et al . Human mitochondril DNA deletion associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat genet 2001;28:223-31.   Back to cited text no. 15    
16.Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001;28:211-2.  Back to cited text no. 16    
17.Van Goethem G, Martin JJ, Van Broeckhoven C. Progressive external ophthalmoplegia and multiple mitochondrial DNA deletions . Acta Neurol Belg 2002;102:39-42.  Back to cited text no. 17    
18.Suomalainen A, Kaukonen J, Amati P, Timonen R, Haltia M, Weissenbach J, et al . An autosomal locus predisposing to deletions of mitochondrial DNA . Nat Genet 1995;9:146-51.  Back to cited text no. 18    
19.Servidei S, Zeviani M, Manfredi G, Ricci E, Silvestri G, Bertini E, et al . Dominantly inherited mitochondrial myopathy with multiple deletions of mitochondrial DNA: clinical, morphologic and biochemical studies. Neurology 1991;41:1053-9.  Back to cited text no. 19    
20.Suomalainen A, Majander A, Wallin M, Setδlδ K, Kontula K, Leinonen H, et al . Autosomal dominant progressive ophthalmoplegia with multiple deletions of mtDNA: clinical, biochemical and molecular genetic features of the 10q-linked disease. Neurology 1997;48:1244-53.  Back to cited text no. 20    
21.Zeviani M, Bresolin N, Gellera C, Bordoni A, Pannaci M, Amati P, et al . Nucleus-driven multiple large scale deletions of the human mitochondrial genome: a new autosomal dominant disease. Am J Hum Genet 1990;47:904-14.  Back to cited text no. 21    
22.Cormier V, R φtig A, Tardieu M, Colonna M, Saudubray JM, Munnich A. Autosomal dominant deletions of the mitochondrial genome in a case of progressive encephalomyopathy. Am J Hum Genet 1991;48:643-8.  Back to cited text no. 22    
23.Kiechl S, Horvath R, Luoma P, Kiechl-Kohlendorfer U, Wallacher-Scholz B, Stucka R, et al . Two families with autosomal dominant progressive external ophthalmoplegia. J Neurol Neurosurg Psychiat 2004;75:1125-8.  Back to cited text no. 23    
24.Deschauer M, Kiefer R, Blakely EL, He L, Zierz S, Turnbull DM, et al . A novel Twinkle gene mutation in autosomal dominant progressive external ophthalmoplegia. Neuromuscul Disord 2003;13:568-72.  Back to cited text no. 24    
25.Agostino A, Valletta L, Chinnery PF, Ferrari G, Carrara F, Taylor RW, et al . Mutations of ANT1, Twinkle and POLG1 in sporadic progressive external ophthalmoplegia (PEO). Neurology 2003;60:1354-6.  Back to cited text no. 25    
26.Arenas J, Briem E, Dahl H, Hutchison W, Lewis S, Martin MA, et al . The V368i mutation in Twinkle does not segregate with AdPEO. Ann Neurol. 2003;53:278.  Back to cited text no. 26    
27.Quigley A, Reardon K, Kapsa R, Dennett X, Byrne E, Thyagarajan D. A Novel Clinical Phenotype of Myopathy, Sensorimotor Neuropathy, Infertility and Hypogonadism with Multiple Mitochondrial DNA Deletions. J Clin Neuromuscul Dis 2001;3:77-82.  Back to cited text no. 27    


    Tables

[Table - 1]

This article has been cited by
1 Identification of a novel twinkle mutation in a family with infantile onset spinocerebellar ataxia by whole exome sequencing
Dündar, H. and Özgül, R.K. and Yalnzoǧlu, D. and Erdem, S. and Oǧuz, K.K. and Tuncel, D. and Temuçin, C.M. and Dursun, A.
Pediatric Neurology. 2012; 46(3): 172-177
[Pubmed]
2 TWINKLE gene mutation: Report of a French family with an autosomal dominant progressive external ophthalmoplegia and literature review
Martin-Negrier, M.-L., Sole, G., Jardel, C., Vital, C., Ferrer, X., Vital, A.
European Journal of Neurology. 2011; 18(3): 436-441
[Pubmed]
3 Disease variants of the human mitochondrial DNA helicase encoded by C10orf2 differentially alter protein stability, nucleotide hydrolysis, and helicase activity
Longley, M.J., Humble, M.M., Sharief, F.S., Copeland, W.C.
Journal of Biological Chemistry. 2010; 285(39): 29690-29702
[Pubmed]
4 The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO
Fratter, C., Gorman, G.S., Stewart, J.D., Buddles, M., Smith, C., Evans, J., Seller, A., Taylor, R.W.
Neurology. 2010; 74(20): 1619-1626
[Pubmed]
5 Finding twinkle in the eyes of a 71-year-old lady: a case report and review of the genotypic and phenotypic spectrum of tw/akkle-related dominant disease
Van Hove, J.L.K., Cunningham, V., Rice, C., Ringel, S.P., Zhang, Q., Chou, P.-C., Truong, C.K., Wong, L.-J.C.
American Journal of Medical Genetics, Part A. 2009; 149(5): 861-867
[Pubmed]
6 A novel Twinkle (PEO1) gene mutation in a Chinese family with adPEO
Liu, Z., Ding, Y., Du, A., Zhang, B., Zhao, G., Ding, M.P.
Molecular Vision. 2008; 14: 1995-2001
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow